New Two-Pronged attack tested for Tough-to-Treat blood cancer
NCT ID NCT06207799
Summary
This study is testing if a drug called elranatamab can help control high-risk multiple myeloma when given before and after a patient's own stem cell transplant. The goal is to see if this approach can eliminate all detectable cancer cells and keep them away for a long time. The study will enroll 40 adults with newly diagnosed, high-risk disease to test the safety and effectiveness of this combined treatment plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.